Medicamen IPO
Medicamen Organics Ltd
₹1,28,000 /4000 sharesMinimum Investment
Medicamen IPO Details
Bidding Dates | Min. Investment | Lot Size | Price Range |
---|
21 Jun ‘24 - 25 Jun ‘24 | ₹1,28,000 | 4,000 | ₹32 - ₹34 |
Medicamen Organics Limited, incorporated in 1995 as Panchdeep Pharmaceuticals, is engaged in the manufacturing of pharmaceutical formulations and products, including tablets, capsules, oral liquids, and ointments. The company operates two WHO-GMP certified plants located in Haridwar.
The product portfolio of Medicamen consists of 84 pharmaceutical products. These belong to the anti-bacterial, anti diarrheal, anti-fungal, anti-diabetic, proton pump inhibitor, multi-vitamin, multi-mineral and non-steroidal anti-inflammatory drug (NSAIDS) categories.
The company has an in-house testing facility and sources its raw materials from FDA-approved sources.
The company exports its products to countries on the African continent, CIS and SAARC countries. It is registered in 13 countries.
The company’s products are marketed across India, Africa, Commonwealth of Independent States (CIS) and countries in south-east Asia by its third-party distributor.;
Managing director
Mr. Bal Kishan Gupta
Parent organisation
Medicamen Organics Ltd
Strengths & Financials of Medicamen
Medicamen Organics holds ISO 9001:2015 certification for quality management systems.
As of September 30, 2023, the company's product range includes 84 products marketed globally under various brand names.
Medicamen Organics has a presence in India and overseas. It also holds approvals for product manufacturing in international markets. This includes countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, the Philippines, Myanmar, Mozambique, Burundi, Kyrgyzstan, and Kenya.
The company’s manufacturing facilities in Ranipur, Haridwar, hold WHO GMP approval.
Medicamen Organics depends on a few customers. Its top 10 customers accounted for 68.67%, 62.00%, 66.45%, and 55.82% of total sales for the six months ending September 30, 2023, and for the years ending March 31, 2023, 2022, and 2021, respectively. Any decline in quality, increased competition, or shift in demand could negatively impact the company.
The company relies heavily on a few key suppliers, with the top 10 suppliers contributing 47.48%, 61.25%, 38.71%, and 32.10% of total purchases for the six months ending September 30, 2023, and for the fiscal years ending March 31, 2023, 2022, and 2021, respectively. Losing any of these major suppliers could disrupt the company’s business operations.
As of September 30, 2023, Medicamen Organics had outstanding secured loans worth Rs 5.84 crore. Inability to service this debt could negatively affect the company.
The company’s directors and promoters are involved in legal proceedings. There are 10 criminal cases against the company, involving a total of Rs 0.16 crore, and 15 tax-related cases involving a total of Rs 1.89 crore. Any adverse judgments in these cases could hurt the company’s business
Medicamen Financials
*All values are in Rs. Cr
Application Details of Medicamen IPO
Apply as | Price band | Apply Range |
---|
Regular | ₹32 - 34 | ₹2 - 5 Lakh |
High Networth Individual | ₹32 - 34 | ₹2 - 5 Lakh |
For Medicamen IPO, eligible investors can apply as Regular.